Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
The new campus has been designed as an employee-centred experience and ecosystem zone
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
An accomplished R&D leader and champion of the application of AI to drug discovery
Subscribe To Our Newsletter & Stay Updated
